After RA, Anakinra Proves to be an Effective Treatment Alternative for Acute Gout Flares

Primary tabs

After RA, Anakinra Proves to be an Effective Treatment Alternative for Acute Gout Flares

Anakinra, a recombinant IL-1β receptor antagonist, was proved to be an effective treatment alternative for the acute gout flares as explained in the results of a randomized, double-blind, placebo-controlled, active comparator, non-inferiority (NI) trial study published in 'Rheumatology'.  Carly A Janssen et al. examined the efficacy and safety of anakinra in treating acute gout flares. 

The patients with a crystal-proven acute gout flare were randomized (1:1) to treatment with anakinra or treatment as usual (free choice: either colchicine, naproxen or prednisone). Primary end-point comprised of the change in pain between baseline and averaged pain score on days 2 to 4 as measured on a five-point rating scale. In the analysis of covariance model, the NI of anakinra would be exhibited in the upper bound of the 95% CI of the numeric difference in changed pain scores between treatment groups did not exceed the NI limit of 0.4 in favour of treatment as usual, in the per-protocol (PP) and intention-to-treat (ITT) populations. The secondary outcomes comprised of safety assessments, swelling, tenderness, improvement in pain and treatment response after 5 days, calculated via the linear mixed models and binary logistic regression models. Overall, 88 patients were included in this study (43 patients receiving anakinra and 45 treatment as usual). The study resulted in non-inferiority of Anakira to treatment as usual in both the PP and ITT populations. In either of the treatment arm, no unexpected or uncommon (serious) adverse events were noticed. As per the analyses of the secondary outcomes, the patients in both the groups described similar significant reductions in their gout symptoms. The study researchers concluded, "Anakinra is an effective treatment alternative for acute gout flares".




Original title of article:

Anakinra for the treatment of acute gout flares: a randomized, double-blind, placebo-controlled, active-comparator, non-inferiority trial.


Carly A Janssen et al.

Therapeutic, Anakinra, Colchicine, Naproxen, Prednisone, Gout, Acute gout flares, Toe, Pain, Recombinant IL-1β receptor antagonist, NSAIDs, Randomized double-blind placebo-controlled active-comparator non-inferiority trial, Five-point rating scale, Efficacy, Safety
Log in or register to post comments